Literature DB >> 28577854

Diabetes with early kidney involvement may shorten life expectancy by 16 years.

Chi Pang Wen1, Chia Hsuin Chang2, Min Kuang Tsai3, June Han Lee3, Po Jung Lu3, Shan Pou Tsai4, Christopher Wen5, Chien Hua Chen6, Chih Wen Kao7, Chwen Keng Tsao4, Xifeng Wu8.   

Abstract

This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related groups were identified and compared: diabetes without CKD, early diabetic kidney disease, and early CKD without diabetes. Deaths were ascertained through the National Death Registry. One-third of diabetics had early kidney disease, and approximately two-thirds of patients were classified with early CKD due to proteinuria. Patients with early diabetic kidney disease had more lifestyle risks such as inactivity or obesity, which characteristically amplified excess mortality by up to five times. The three-fold increase in all-cause mortality (hazard ratio 3.16) and a 16-year loss in life expectancy made early diabetic kidney disease a serious and yet often overlooked disease, with most patients unaware of their kidney involvement. Mortality for early diabetic kidney disease was nearly twice as high as that for early CKD (hazard ratio 2.01) or diabetes without CKD (hazard ratio 1.79). The 16-year life span loss is much worse than individually from early CKD (six years) or diabetes (ten years). Thus, identifying early proteinuria among diabetic patients and realizing the importance of reducing lifestyle risks like inactivity is a clinical challenge, but can save lives.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney diseases; diabetes; life expectancy; mortality

Mesh:

Substances:

Year:  2017        PMID: 28577854     DOI: 10.1016/j.kint.2017.01.030

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

Review 1.  Value of Doppler ultrasound in early detection of diabetic kidney disease: A systematic review and meta-analysis.

Authors:  Heather Kilgour Venables; Yaw Amo Wiafe; Theophilus Kofi Adu-Bredu
Journal:  Ultrasound       Date:  2020-12-08

2.  Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.

Authors:  Ataru Igarashi; Keiko Maruyama-Sakurai; Anna Kubota; Hiroki Akiyama; Toshitaka Yajima; Shun Kohsaka; Hiroaki Miyata
Journal:  Diabetes Ther       Date:  2022-06-16       Impact factor: 3.595

Review 3.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

4.  Increased risk of new-onset type 2 diabetes in people with chronic kidney disease.

Authors:  I-Kuan Wang; Tsung-Hsun Tsai; Yi-Chih Hung; Tzu-Yuan Wang; Tzung-Hai Yen; Cheng-Li Lin; Fung-Chang Sung
Journal:  Int Urol Nephrol       Date:  2019-01-28       Impact factor: 2.370

5.  Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Authors:  Luis M Ruilope; Rajiv Agarwal; Stefan D Anker; George L Bakris; Gerasimos Filippatos; Christina Nowack; Peter Kolkhof; Amer Joseph; Nicole Mentenich; Bertram Pitt
Journal:  Am J Nephrol       Date:  2019-10-30       Impact factor: 3.754

Review 6.  Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.

Authors:  Gian Paolo Fadini; Stefano Del Prato; Angelo Avogaro; Anna Solini
Journal:  Diabetes Obes Metab       Date:  2021-11-24       Impact factor: 6.408

7.  Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Authors:  Vlado Perkovic; Robert Toto; Mark E Cooper; Johannes F E Mann; Julio Rosenstock; Darren K McGuire; Steven E Kahn; Nikolaus Marx; John H Alexander; Bernard Zinman; Egon Pfarr; Sven Schnaidt; Thomas Meinicke; Maximillian von Eynatten; Jyothis T George; Odd Erik Johansen; Christoph Wanner
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

8.  Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Nienke M A Idzerda; Bergur V Stefansson; Michelle J Pena; David C Sjostrom; David C Wheeler; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2020-09-01       Impact factor: 5.992

9.  Mitochondria transfer from mesenchymal stem cells structurally and functionally repairs renal proximal tubular epithelial cells in diabetic nephropathy in vivo.

Authors:  Naoto Konari; Kanna Nagaishi; Shin Kikuchi; Mineko Fujimiya
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

Review 10.  Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Authors:  Nina Vodošek Hojs; Sebastjan Bevc; Robert Ekart; Nejc Piko; Tadej Petreski; Radovan Hojs
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.